A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs CC 90002 (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 28 Sep 2017 Planned End Date changed from 21 Jan 2018 to 13 Jun 2019.
- 28 Sep 2017 Planned primary completion date changed from 21 Jan 2018 to 13 Jun 2019.
- 09 May 2017 Planned number of patients changed from 100 to 65.